| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 15 | 2023 | 651 | 3.380 |
Why?
|
| Exercise | 23 | 2025 | 469 | 3.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 17 | 2019 | 324 | 3.010 |
Why?
|
| Pediatric Obesity | 6 | 2024 | 69 | 2.700 |
Why?
|
| Insulin Resistance | 19 | 2019 | 172 | 2.700 |
Why?
|
| Muscle, Skeletal | 28 | 2013 | 622 | 2.590 |
Why?
|
| Overweight | 6 | 2019 | 108 | 2.010 |
Why?
|
| Mitochondria, Muscle | 16 | 2012 | 40 | 2.000 |
Why?
|
| Blood Glucose | 20 | 2022 | 307 | 1.900 |
Why?
|
| Indians, North American | 6 | 2020 | 515 | 1.860 |
Why?
|
| Energy Metabolism | 10 | 2022 | 184 | 1.810 |
Why?
|
| Adolescent | 29 | 2024 | 2996 | 1.800 |
Why?
|
| Cardiovascular Diseases | 9 | 2017 | 357 | 1.780 |
Why?
|
| Body Composition | 13 | 2019 | 262 | 1.690 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2022 | 123 | 1.650 |
Why?
|
| Muscle Proteins | 15 | 2012 | 55 | 1.630 |
Why?
|
| Insulin | 21 | 2017 | 314 | 1.560 |
Why?
|
| Arteries | 4 | 2014 | 65 | 1.530 |
Why?
|
| Postprandial Period | 4 | 2022 | 43 | 1.480 |
Why?
|
| Aging | 16 | 2012 | 960 | 1.460 |
Why?
|
| Lipoproteins, LDL | 2 | 2024 | 36 | 1.420 |
Why?
|
| Lipoproteins, HDL | 2 | 2024 | 41 | 1.410 |
Why?
|
| Male | 62 | 2025 | 13034 | 1.380 |
Why?
|
| Exercise Therapy | 4 | 2018 | 80 | 1.360 |
Why?
|
| Child | 19 | 2024 | 2163 | 1.350 |
Why?
|
| Mitochondrial Proteins | 12 | 2012 | 71 | 1.250 |
Why?
|
| Health Promotion | 4 | 2025 | 171 | 1.160 |
Why?
|
| Female | 49 | 2025 | 14658 | 1.160 |
Why?
|
| Vascular Stiffness | 3 | 2024 | 41 | 1.140 |
Why?
|
| Oxidative Stress | 5 | 2016 | 630 | 1.130 |
Why?
|
| Humans | 70 | 2025 | 27175 | 1.120 |
Why?
|
| Adenosine Triphosphate | 15 | 2012 | 116 | 1.100 |
Why?
|
| Proteins | 8 | 2012 | 245 | 1.060 |
Why?
|
| Amino Acids | 7 | 2019 | 82 | 1.010 |
Why?
|
| Mitochondria | 11 | 2020 | 333 | 0.970 |
Why?
|
| Blood Proteins | 2 | 2024 | 64 | 0.960 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2024 | 66 | 0.910 |
Why?
|
| Fatty Liver | 1 | 2024 | 55 | 0.890 |
Why?
|
| Heart Rate | 5 | 2022 | 375 | 0.890 |
Why?
|
| Vascular Resistance | 3 | 2013 | 50 | 0.870 |
Why?
|
| Nerve Growth Factors | 2 | 2014 | 24 | 0.870 |
Why?
|
| Serpins | 2 | 2014 | 31 | 0.860 |
Why?
|
| Biomarkers | 5 | 2024 | 736 | 0.830 |
Why?
|
| Glucose Tolerance Test | 5 | 2017 | 59 | 0.780 |
Why?
|
| Eye Proteins | 2 | 2014 | 197 | 0.760 |
Why?
|
| Adult | 34 | 2025 | 7510 | 0.760 |
Why?
|
| Oxidation-Reduction | 8 | 2022 | 353 | 0.750 |
Why?
|
| Physical Fitness | 5 | 2013 | 61 | 0.740 |
Why?
|
| Body Mass Index | 10 | 2017 | 385 | 0.700 |
Why?
|
| Leg | 3 | 2012 | 131 | 0.680 |
Why?
|
| High-Intensity Interval Training | 1 | 2020 | 9 | 0.670 |
Why?
|
| Young Adult | 12 | 2024 | 2636 | 0.660 |
Why?
|
| Financial Support | 1 | 2018 | 9 | 0.610 |
Why?
|
| Adipose Tissue | 3 | 2019 | 181 | 0.600 |
Why?
|
| Physical Endurance | 5 | 2008 | 91 | 0.590 |
Why?
|
| Reward | 1 | 2018 | 45 | 0.580 |
Why?
|
| DNA, Mitochondrial | 10 | 2013 | 82 | 0.570 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2024 | 67 | 0.570 |
Why?
|
| Peptide Hormones | 1 | 2017 | 4 | 0.570 |
Why?
|
| Prednisone | 2 | 2009 | 51 | 0.560 |
Why?
|
| Rest | 2 | 2015 | 94 | 0.550 |
Why?
|
| Glucocorticoids | 2 | 2009 | 114 | 0.540 |
Why?
|
| Risk Factors | 9 | 2019 | 2043 | 0.540 |
Why?
|
| Ergometry | 1 | 2016 | 7 | 0.540 |
Why?
|
| Spinal Dysraphism | 1 | 2016 | 14 | 0.530 |
Why?
|
| Cerebral Palsy | 1 | 2016 | 31 | 0.520 |
Why?
|
| Glycemic Index | 1 | 2016 | 5 | 0.520 |
Why?
|
| Adiposity | 2 | 2016 | 88 | 0.520 |
Why?
|
| Glucose | 3 | 2013 | 198 | 0.500 |
Why?
|
| Amino Acids, Branched-Chain | 3 | 2019 | 8 | 0.490 |
Why?
|
| Homeostasis | 2 | 2013 | 114 | 0.490 |
Why?
|
| Motivation | 3 | 2025 | 210 | 0.480 |
Why?
|
| Elasticity | 2 | 2013 | 49 | 0.480 |
Why?
|
| Hyperemia | 2 | 2013 | 31 | 0.470 |
Why?
|
| Phenylalanine | 5 | 2008 | 24 | 0.470 |
Why?
|
| Blood Pressure | 3 | 2024 | 351 | 0.460 |
Why?
|
| Triiodothyronine | 2 | 2006 | 20 | 0.450 |
Why?
|
| Lipids | 5 | 2017 | 199 | 0.450 |
Why?
|
| Trans-Activators | 2 | 2013 | 114 | 0.440 |
Why?
|
| Diabetes, Gestational | 1 | 2015 | 67 | 0.440 |
Why?
|
| Cross-Over Studies | 6 | 2022 | 132 | 0.440 |
Why?
|
| Motor Activity | 4 | 2013 | 145 | 0.440 |
Why?
|
| Muscular Atrophy | 3 | 2008 | 31 | 0.420 |
Why?
|
| Diabetic Angiopathies | 3 | 2020 | 48 | 0.420 |
Why?
|
| Viscera | 1 | 2012 | 18 | 0.410 |
Why?
|
| Organogenesis | 1 | 2012 | 12 | 0.400 |
Why?
|
| Protein Biosynthesis | 4 | 2008 | 109 | 0.400 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 627 | 0.390 |
Why?
|
| Meals | 2 | 2022 | 22 | 0.390 |
Why?
|
| Caloric Restriction | 3 | 2012 | 73 | 0.390 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 36 | 0.390 |
Why?
|
| Hypertension | 2 | 2012 | 304 | 0.380 |
Why?
|
| Hyperglycemia | 1 | 2012 | 78 | 0.370 |
Why?
|
| Liver | 6 | 2024 | 424 | 0.370 |
Why?
|
| Models, Biological | 2 | 2012 | 448 | 0.360 |
Why?
|
| Hyperthyroidism | 3 | 2013 | 11 | 0.350 |
Why?
|
| Diet | 2 | 2009 | 225 | 0.350 |
Why?
|
| Research Design | 2 | 2019 | 173 | 0.340 |
Why?
|
| Insulin Antagonists | 1 | 2009 | 1 | 0.330 |
Why?
|
| Oklahoma | 3 | 2019 | 977 | 0.330 |
Why?
|
| RNA, Messenger | 10 | 2013 | 647 | 0.330 |
Why?
|
| Video Games | 1 | 2009 | 20 | 0.320 |
Why?
|
| Metabolic Syndrome | 2 | 2013 | 78 | 0.320 |
Why?
|
| Hormones | 3 | 2008 | 41 | 0.320 |
Why?
|
| Case-Control Studies | 2 | 2024 | 708 | 0.320 |
Why?
|
| Cytoplasm | 2 | 2006 | 57 | 0.320 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2008 | 6 | 0.310 |
Why?
|
| Cardiorespiratory Fitness | 2 | 2020 | 8 | 0.310 |
Why?
|
| Compliance | 3 | 2014 | 21 | 0.310 |
Why?
|
| Oxygen Consumption | 3 | 2001 | 179 | 0.300 |
Why?
|
| Citrate (si)-Synthase | 9 | 2013 | 23 | 0.300 |
Why?
|
| Human Growth Hormone | 1 | 2007 | 14 | 0.290 |
Why?
|
| Myosin Heavy Chains | 2 | 2005 | 22 | 0.290 |
Why?
|
| Aged | 15 | 2009 | 5232 | 0.290 |
Why?
|
| Rats | 12 | 2013 | 1544 | 0.280 |
Why?
|
| Membrane Transport Proteins | 3 | 2002 | 66 | 0.270 |
Why?
|
| Middle Aged | 15 | 2025 | 6918 | 0.270 |
Why?
|
| Diabetic Cardiomyopathies | 2 | 2017 | 6 | 0.260 |
Why?
|
| Glycolysis | 1 | 2006 | 82 | 0.260 |
Why?
|
| Double-Blind Method | 8 | 2015 | 405 | 0.260 |
Why?
|
| Animals | 18 | 2019 | 10082 | 0.250 |
Why?
|
| Dietary Fats | 2 | 2022 | 58 | 0.240 |
Why?
|
| Deoxyguanosine | 1 | 2005 | 14 | 0.240 |
Why?
|
| Risk | 2 | 2017 | 133 | 0.240 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2005 | 50 | 0.240 |
Why?
|
| Kinetics | 7 | 2008 | 538 | 0.230 |
Why?
|
| Brain Chemistry | 1 | 2004 | 22 | 0.230 |
Why?
|
| Mitochondria, Liver | 1 | 2004 | 12 | 0.230 |
Why?
|
| Calorimetry, Indirect | 3 | 2009 | 14 | 0.220 |
Why?
|
| Feasibility Studies | 1 | 2025 | 191 | 0.220 |
Why?
|
| Glucose Intolerance | 1 | 2003 | 22 | 0.220 |
Why?
|
| Lipid Metabolism | 1 | 2004 | 122 | 0.210 |
Why?
|
| Sequence Deletion | 1 | 2003 | 65 | 0.210 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 92 | 0.210 |
Why?
|
| Tyrosine | 2 | 2003 | 92 | 0.210 |
Why?
|
| Sex Factors | 1 | 2024 | 451 | 0.210 |
Why?
|
| Leukocytes | 1 | 2003 | 69 | 0.210 |
Why?
|
| Liver Cirrhosis | 1 | 2003 | 67 | 0.210 |
Why?
|
| Hypoglycemic Agents | 3 | 2015 | 106 | 0.200 |
Why?
|
| Peptides | 1 | 2024 | 283 | 0.200 |
Why?
|
| Rats, Sprague-Dawley | 8 | 2012 | 538 | 0.190 |
Why?
|
| Age Factors | 4 | 2013 | 724 | 0.190 |
Why?
|
| Telemedicine | 1 | 2025 | 163 | 0.190 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 752 | 0.190 |
Why?
|
| Aged, 80 and over | 6 | 2009 | 1943 | 0.180 |
Why?
|
| Carrier Proteins | 3 | 2002 | 246 | 0.180 |
Why?
|
| Biopsy | 4 | 2009 | 202 | 0.180 |
Why?
|
| Exercise Test | 4 | 2013 | 248 | 0.180 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2020 | 21 | 0.180 |
Why?
|
| Glucose Clamp Technique | 5 | 2015 | 12 | 0.170 |
Why?
|
| Pulse Wave Analysis | 1 | 2020 | 29 | 0.170 |
Why?
|
| Myocardium | 3 | 2012 | 179 | 0.170 |
Why?
|
| Walking | 2 | 2013 | 130 | 0.170 |
Why?
|
| Pilot Projects | 2 | 2020 | 398 | 0.160 |
Why?
|
| Smoking Cessation | 1 | 2025 | 399 | 0.160 |
Why?
|
| Interferon Regulatory Factors | 1 | 2019 | 58 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 64 | 0.160 |
Why?
|
| Muscle Fatigue | 2 | 2002 | 76 | 0.160 |
Why?
|
| Weight Loss | 1 | 2019 | 72 | 0.160 |
Why?
|
| Community-Based Participatory Research | 1 | 2019 | 33 | 0.160 |
Why?
|
| Signal Transduction | 1 | 2005 | 1374 | 0.160 |
Why?
|
| Gene Expression Profiling | 5 | 2012 | 438 | 0.160 |
Why?
|
| Dietary Proteins | 2 | 2008 | 34 | 0.150 |
Why?
|
| Rural Population | 1 | 2019 | 98 | 0.150 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 3 | 0.140 |
Why?
|
| Dehydroepiandrosterone | 2 | 2007 | 14 | 0.140 |
Why?
|
| Dietary Carbohydrates | 1 | 1997 | 25 | 0.140 |
Why?
|
| Transcription, Genetic | 3 | 2007 | 400 | 0.140 |
Why?
|
| Transcription Factors | 3 | 2013 | 514 | 0.130 |
Why?
|
| Prevalence | 2 | 2015 | 475 | 0.130 |
Why?
|
| Eating | 2 | 2013 | 70 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 936 | 0.130 |
Why?
|
| Child of Impaired Parents | 1 | 2015 | 6 | 0.120 |
Why?
|
| Carbon Isotopes | 5 | 2012 | 43 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 990 | 0.120 |
Why?
|
| Adiponectin | 1 | 2015 | 29 | 0.120 |
Why?
|
| Peroxidase | 1 | 2015 | 38 | 0.120 |
Why?
|
| Electric Impedance | 1 | 2015 | 30 | 0.120 |
Why?
|
| Reference Values | 4 | 2006 | 199 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2014 | 864 | 0.120 |
Why?
|
| Leptin | 1 | 2015 | 67 | 0.120 |
Why?
|
| Birth Weight | 1 | 2015 | 63 | 0.120 |
Why?
|
| Infant, Newborn | 2 | 2015 | 851 | 0.120 |
Why?
|
| Absorptiometry, Photon | 1 | 2015 | 100 | 0.120 |
Why?
|
| Glycated Hemoglobin A | 1 | 2015 | 64 | 0.120 |
Why?
|
| Prospective Studies | 3 | 2015 | 1224 | 0.120 |
Why?
|
| Child Development | 1 | 2015 | 72 | 0.110 |
Why?
|
| RNA | 3 | 2005 | 106 | 0.110 |
Why?
|
| Pregnancy | 2 | 2015 | 1153 | 0.110 |
Why?
|
| Disease Progression | 2 | 2020 | 458 | 0.110 |
Why?
|
| Thyroid Hormones | 1 | 2013 | 24 | 0.110 |
Why?
|
| Hormone Replacement Therapy | 2 | 2006 | 8 | 0.110 |
Why?
|
| Energy Intake | 4 | 2013 | 69 | 0.110 |
Why?
|
| Leucine | 4 | 2012 | 20 | 0.100 |
Why?
|
| Cholesterol, HDL | 1 | 2013 | 59 | 0.100 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2013 | 16 | 0.100 |
Why?
|
| Mitochondrial Turnover | 1 | 2012 | 2 | 0.100 |
Why?
|
| Splanchnic Circulation | 1 | 2012 | 7 | 0.100 |
Why?
|
| Metabolic Diseases | 1 | 2013 | 16 | 0.100 |
Why?
|
| Diazoxide | 1 | 2012 | 2 | 0.100 |
Why?
|
| Sarcolemma | 1 | 2012 | 6 | 0.100 |
Why?
|
| Myofibrils | 1 | 2012 | 5 | 0.100 |
Why?
|
| Cardiotonic Agents | 1 | 2012 | 25 | 0.100 |
Why?
|
| Oxidative Phosphorylation | 3 | 2012 | 24 | 0.100 |
Why?
|
| Blood Flow Velocity | 1 | 2012 | 63 | 0.100 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 22 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 76 | 0.100 |
Why?
|
| Manometry | 1 | 2011 | 38 | 0.100 |
Why?
|
| Blotting, Western | 4 | 2012 | 506 | 0.090 |
Why?
|
| Triglycerides | 3 | 2023 | 120 | 0.090 |
Why?
|
| Rats, Inbred F344 | 3 | 2013 | 168 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 154 | 0.090 |
Why?
|
| Proteomics | 3 | 2012 | 177 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 811 | 0.090 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2009 | 4 | 0.080 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 20 | 0.080 |
Why?
|
| Testosterone | 2 | 2007 | 68 | 0.080 |
Why?
|
| Kidney | 2 | 2008 | 275 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 213 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 42 | 0.080 |
Why?
|
| Carotid Arteries | 1 | 2009 | 52 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 56 | 0.080 |
Why?
|
| Methylprednisolone | 1 | 2009 | 15 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 324 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2013 | 388 | 0.080 |
Why?
|
| Physical Exertion | 1 | 2009 | 102 | 0.080 |
Why?
|
| United States | 1 | 2015 | 2063 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2007 | 291 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 472 | 0.070 |
Why?
|
| Life Style | 1 | 2008 | 84 | 0.070 |
Why?
|
| Uncoupling Protein 3 | 3 | 2002 | 5 | 0.070 |
Why?
|
| Uncoupling Protein 2 | 3 | 2002 | 5 | 0.070 |
Why?
|
| Ion Channels | 3 | 2002 | 23 | 0.070 |
Why?
|
| Pruritus Ani | 1 | 2007 | 1 | 0.070 |
Why?
|
| Antipruritics | 1 | 2007 | 3 | 0.070 |
Why?
|
| Postmenopause | 1 | 2007 | 83 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 305 | 0.070 |
Why?
|
| Electron Transport Complex IV | 3 | 2003 | 40 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2007 | 88 | 0.070 |
Why?
|
| Gene Expression | 3 | 2003 | 407 | 0.070 |
Why?
|
| Physical Conditioning, Animal | 1 | 2006 | 38 | 0.070 |
Why?
|
| Skin | 1 | 2007 | 140 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2009 | 591 | 0.060 |
Why?
|
| Health | 1 | 2005 | 12 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2020 | 597 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2005 | 86 | 0.060 |
Why?
|
| Endocrinology | 1 | 2004 | 3 | 0.060 |
Why?
|
| Causality | 1 | 2004 | 14 | 0.060 |
Why?
|
| Luminescent Measurements | 1 | 2004 | 30 | 0.060 |
Why?
|
| Physiology | 1 | 2004 | 8 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2004 | 166 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 218 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2007 | 188 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 163 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 128 | 0.060 |
Why?
|
| Radioactive Tracers | 1 | 2003 | 1 | 0.060 |
Why?
|
| Time Factors | 3 | 2013 | 1573 | 0.050 |
Why?
|
| Regional Blood Flow | 1 | 2004 | 163 | 0.050 |
Why?
|
| Nuclear Respiratory Factors | 1 | 2003 | 1 | 0.050 |
Why?
|
| NF-E2-Related Factor 1 | 1 | 2003 | 2 | 0.050 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2003 | 4 | 0.050 |
Why?
|
| Sample Size | 1 | 2003 | 17 | 0.050 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2003 | 23 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2023 | 22 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2003 | 115 | 0.050 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2003 | 62 | 0.050 |
Why?
|
| Exercise Tolerance | 1 | 2003 | 82 | 0.050 |
Why?
|
| Vitamin E | 1 | 2002 | 11 | 0.050 |
Why?
|
| Base Sequence | 1 | 2003 | 575 | 0.050 |
Why?
|
| Heart | 2 | 2001 | 221 | 0.050 |
Why?
|
| Infant | 2 | 2015 | 971 | 0.050 |
Why?
|
| Cell Respiration | 1 | 2001 | 9 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2001 | 118 | 0.050 |
Why?
|
| Mutagenesis | 1 | 2001 | 45 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 245 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1041 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 2001 | 56 | 0.050 |
Why?
|
| Hyperinsulinism | 2 | 2012 | 16 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 29 | 0.040 |
Why?
|
| Mice | 3 | 2019 | 4472 | 0.040 |
Why?
|
| Antioxidants | 1 | 2002 | 223 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 99 | 0.040 |
Why?
|
| Body Weight | 3 | 2009 | 246 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 482 | 0.040 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2009 | 22 | 0.040 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 1997 | 12 | 0.040 |
Why?
|
| Anaerobic Threshold | 1 | 1997 | 19 | 0.040 |
Why?
|
| Beverages | 1 | 1997 | 24 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2020 | 279 | 0.030 |
Why?
|
| Estradiol | 2 | 2007 | 175 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2015 | 38 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 10 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 1496 | 0.030 |
Why?
|
| Metformin | 1 | 2015 | 34 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 202 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2007 | 262 | 0.030 |
Why?
|
| Hypothalamus | 1 | 2013 | 29 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2013 | 17 | 0.030 |
Why?
|
| Body Weights and Measures | 1 | 2013 | 18 | 0.030 |
Why?
|
| Quality of Life | 2 | 2007 | 467 | 0.030 |
Why?
|
| Electron Transport Complex II | 1 | 2012 | 5 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2013 | 27 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2012 | 13 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 94 | 0.030 |
Why?
|
| Anthropometry | 1 | 2013 | 93 | 0.030 |
Why?
|
| Insulin, Regular, Human | 1 | 2012 | 1 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2012 | 94 | 0.030 |
Why?
|
| Self Report | 1 | 2013 | 116 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 197 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 101 | 0.020 |
Why?
|
| Calcium | 1 | 2012 | 232 | 0.020 |
Why?
|
| Adult Children | 1 | 2011 | 1 | 0.020 |
Why?
|
| Transcriptome | 1 | 2012 | 205 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 567 | 0.020 |
Why?
|
| C-Peptide | 1 | 2009 | 8 | 0.020 |
Why?
|
| Glucagon | 1 | 2009 | 11 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 38 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2009 | 163 | 0.020 |
Why?
|
| Sirtuins | 1 | 2008 | 17 | 0.020 |
Why?
|
| Sirtuin 3 | 1 | 2008 | 18 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 48 | 0.020 |
Why?
|
| Nutritional Requirements | 1 | 2008 | 9 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2008 | 19 | 0.020 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2007 | 5 | 0.020 |
Why?
|
| Estrone | 1 | 2007 | 5 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 113 | 0.020 |
Why?
|
| Ointments | 1 | 2007 | 6 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2007 | 28 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 143 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2006 | 68 | 0.020 |
Why?
|
| Cholesterol | 1 | 2007 | 181 | 0.020 |
Why?
|
| Bone Density | 1 | 2006 | 99 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 448 | 0.020 |
Why?
|
| Global Health | 1 | 2003 | 43 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 76 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 932 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2003 | 150 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2003 | 87 | 0.010 |
Why?
|
| Thermogenesis | 1 | 2003 | 12 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 135 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 46 | 0.010 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2002 | 45 | 0.010 |
Why?
|
| Vitamin A | 1 | 2002 | 25 | 0.010 |
Why?
|
| Selenium | 1 | 2002 | 17 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2002 | 68 | 0.010 |
Why?
|
| Keto Acids | 1 | 2001 | 3 | 0.010 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2001 | 7 | 0.010 |
Why?
|
| RNA, Transfer, Leu | 1 | 2001 | 5 | 0.010 |
Why?
|
| Swine, Miniature | 1 | 2001 | 4 | 0.010 |
Why?
|
| Oxygen | 1 | 2003 | 230 | 0.010 |
Why?
|
| Body Fluids | 1 | 2001 | 18 | 0.010 |
Why?
|
| Swine | 1 | 2001 | 221 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2007 | 2289 | 0.010 |
Why?
|